Coffee may eventually turn cancer treatments on and off.

Without thinking twice, the majority of us reach for coffee. Scientists are now transforming that well-known shock into something even more accurate: a switch that can regulate gene editing within living cells.

Caffeine and CRISPR, the gene-editing technique formerly known as clustered regularly interspaced short palindromic repeats, have been combined by researchers at the Texas A&M Health Institute of Biosciences and Technology. The idea is to program cells ahead of time, then use a modest, controlled dosage of caffeine to either activate or halt their behaviour.

Converting coffee into a switch for cells

The tactic is based on chemogenetics, a technique that guides created cells using particular chemicals. Chemogenetics only operates in cells that are made to respond, as opposed to medications that affect multiple tissues and travel throughout the body. It is regulated and targeted.

Yubin Zhou has years of experience researching cancer at the cellular, genetic, and epigenetic levels. He is the director of the Center for Translational Cancer Research at the Institute of Biosciences and Technology.

His lab has developed methods to use CRISPR and chemogenetic systems to better understand and possibly treat diabetes, cancer, and other chronic illnesses, as documented in more than 180 scholarly articles.

How gene editing is activated by caffeine

Long before anyone drinks coffee, the process starts. First, scientists use gene transfer procedures to prepare cells. Three components are produced by the inserted genes: the CRISPR apparatus itself, a matching partner protein, and a nanobody. These components are produced spontaneously once within the cell.

A modest amount of caffeine, such as 20 mg from coffee, chocolate, or soda, serves as a signal. It results in the binding of the nanobody to its companion protein. This binding activates CRISPR, which subsequently modifies particular genes within the cell.

The scientists discovered that caffeine and its metabolites, including theobromine, which is common in chocolate or cocoa, can cause this reaction in lab animals and make CRISPR-based editing possible.

The activation window only lasts a few hours, which is about how long it takes for the body to process caffeine. Researchers have strict control over when gene editing takes place thanks to that brief timeframe.

Certain medications reverse the process.

Activation is not the end of control. The researchers found that the process can be reversed by some medications. Rapamycin, an immunosuppressant that has been used for a long time to prevent organ rejection following transplantation, is one of them. Rapamycin prevents white blood cells from attacking foreign tissue by reducing their activity.

Zhou added, "You can also engineer these antibody-like molecules to work with rapamycin-inducible systems, so you can achieve the opposite effect by adding a different drug like rapamycin."

"If proteins A and B are initially separated, for instance, adding caffeine will bring them together; if proteins A and B are initially together, adding a medication like rapamycin may cause them to dissociate."

Doctors could separate the linked proteins and stop additional gene editing by administering rapamycin. A real on-and-off mechanism is produced as a result.

In a clinical context, doctors may halt gene activity and resume it later if a patient suffers from stress or adverse effects. This type of coordinated start and stop control is not available in many gene-editing techniques available today.

A novel T-cell lever

For immunological T cells, which serve as the body's memory against infection, the strategy holds particular potential. CAR-T and other modified T cell treatments are already being utilised to treat cancer.

Doctors may be able to determine when those cells become more aggressive against tumours by adding caffeine-responsive components.

"It's pretty modular," Zhou remarked. "You can incorporate it into CRISPR and chimeric antigen receptor T (CAR-T) cells, as well as if you wish to induce the expression of therapeutic genes like insulin or other things, and this is fully tunable in a very precisely controlled manner."

Consequences outside of cancer

Beyond cancer, the same platform might be used. Zhou thinks his team's "caffebodies," which are specifically designed nanobodies that react to caffeine, may one day aid in the management of diabetes.

It may be possible to engineer cells to produce more insulin in response to a detected caffeine signal. The idea isn't just about insulin. It can be modified to regulate other molecules that influence metabolic pathways and immunological responses.

"The idea of repurposing popular medications and even everyday food ingredients like caffeine to do completely new tricks excites us," Zhou stated. "Moleculars like caffeine or rapamycin can function as precise control signals for advanced cell and gene therapies, rather than as therapies themselves."

This method provides a useful route to translation because these molecules are already well understood. One day, we hope, doctors will be able to safely and reversibly fine-tune potent medicines using straightforward, well-known inputs.